Gut-liver-axis microphysiological system for studying cellular fluidic shear stress and inter-tissue interaction
Open accessPreprint — published as 10.1063/5.0088232 · Paper page
Abstract
Gut-liver-axis (GLA) is a fundamental interaction between the gut and liver for maintaining human health. To clarify the physiological and pathological roles of GLA in the human body, a GLA microphysiological system (GLA-MPS) holds great potential. However, in current GLA-MPS, the importance of a physiologically relevant flow for gut and liver cells’ cultivation is not fully addressed. In addition, the integration of individual organ perfusion, circulation flow, and organ tissue functions in a single device has not been achieved. Here, we introduce a GLA-MPS by integrating two cell culture chambers with individually applied perfusion flows and a circulation channel with an on-chip pneumatic micropump under cell culture chambers via a porous membrane for interconnecting them. We analyzed the fluid shear stress (FSS) with computational fluid dynamics simulations and confirmed that the physiologically relevant FSS (i.e., 8 × 10 −3 and 1.2 × 10 −7 dyne cm −2 ) could be applied for the gut (Caco-2) and liver (HepG2) cells, respectively. Under physiologically relevant flow, the Caco-2 and HepG2 cells in the GLA-MPS maintained a cell survival rate of 95% and 92%, respectively; further, they enhanced the expression of functional proteins such as zonula occludens 1 (ZO-1) and albumin (ALB), respectively. Thus, the presented GLA-MPS can be adapted as an advanced in vitro model in a wide range of applications for disease modeling associated with inter-tissue interactions, such as fatty liver diseases.
AI snapshot
Written from the paper’s full text.
TL;DR
The paper presents a four-layer gut-liver-axis microphysiological system (GLA-MPS) that applies separate perfusion flows to Caco-2 gut and HepG2 liver chambers while connecting them by on-chip micropump-driven circulation through a porous membrane. It reports physiologically relevant fluid shear stress, high cell viability, enhanced functional protein expression, and barrier function under optimized flow.
Key findings
- CFD estimated apical gut FSS of 8 × 10⁻³ to 2 × 10⁻² dyne cm⁻² under 2–5 μL min⁻¹ perfusion, and basal/circulation FSS of 1 × 10⁻⁸ to 1.2 × 10⁻⁷ dyne cm⁻² through a 20-μm-thick porous membrane.
- After 8 days with circulation flow, Caco-2 and HepG2 cells showed 95% and 92% viability, respectively.
- ZO-1 expression in Caco-2 increased with gut perfusion at 5 μL min⁻¹ (FSS = 2 × 10⁻² dyne cm⁻²), while albumin expression in HepG2 increased when circulation flow increased from 0 to 61 nL min⁻¹.
- The micropump produced 22–61 nL min⁻¹ circulation at 1 Hz and 50–150 kPa, giving a 1.5%–9% exchange ratio in 1 min versus approximately 0.25%–1% in other GLA-MPSs; the device required only 1.5 × 10⁴ cells per chamber versus 3 × 10⁵ for 24-well inserts.
Methods
- The GLA-MPS was fabricated from four PDMS layers plus glass: a cell-culture layer with chambers (5.3 mm × 2 mm × 360 μm), a porous membrane (5-μm holes, 20-μm pitch and thickness), a circulation layer, and a control layer with an on-chip pneumatic micropump.
- Caco-2 and HepG2 cells were cultured in separate chambers, with gut apical perfusion and closed-loop circulation; readouts included CFD with COMSOL, microbead flow-rate tracing, cell viability assay, immunocytochemistry for ZO-1 and albumin, and FITC-dextran permeability.
- Statistical analysis used Tukey-Kramer and asymptotic Wilcoxon signed-rank tests; flow-rate measurements are reported as mean ± SD (n = 10), and permeability assay as n = 3.
Limitations
- The paper states that the device could be improved by integrating organoid structures, by controlling molecular transport gradients across barrier tissues, and by adding TEER sensors with better accuracy and reproducibility; it also notes that the fluorescent dye used for barrier testing might influence cellular functions.
- Evident from the text: the study used Caco-2 and HepG2 cell lines rather than patient-derived primary cells, and the authors note that primary cells could have patient-to-patient variation; microbiome and other tissue-cell applications are proposed as future work rather than demonstrated here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
14 of 49 cited sources checked · 5 supported · 0 flagged · accuracy not yet measured
- Premisecitation
Reported GLA-MPSs showed better predictive capabilities of organ-to-organ interaction compared to normal static cell-culture models.
“They showed better predictive capabilities of organ to organ interaction, compared to normal static cell-culture models.”
Quote in the paperSubstantial claim4 of 6 sources checked- cites [3] source
- cites [7] 2020, Cell Syst source
The Results section ('Interaction between SCFA, gut and liver MPSs') reports that connecting the gut and liver MPSs changed their phenotypes and gene expression relative to studying them in isolation. This supports the claim that the system reveals organ-to-organ interactions, but the paper does not establish better predictive capability than static cell-culture models; its isolation comparison is not identified as a static-culture comparison. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [8] source
The Results section on bile-acid synthesis reports gut–liver crosstalk in the integrated system, including higher FGF19 in interacting than isolated tissue controls. But those controls were single-tissue MPSs on the same platform, not conventional static cell cultures. The paper does not establish that the system has better predictive capability than static models. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [9] 2020, Lab Chip source
- cites [10] source
The section on recent advances in multi-organ models says static in vitro systems cannot capture multi-organ interactions, while BOC systems can reveal responses not observed with conventional models (page unavailable). That supports the general comparison, but our copy does not establish superior predictive capability specifically for the reported GLA-MPSs. (LLM, conf=0.82)
Experimental — accuracy not yet measured - cites [11] 2021, Micromachines source
The Introduction says multiorgan MPSs can evaluate interorgan interactions in real time and may improve pharmacokinetic predictions. But the paper studies a KIM-Plate, not a system it calls a GLA-MPS, and does not show better predictive capability than static cell-culture models; its static-culture comparison in Results and Discussion §3.1 concerns cell number and morphology. (LLM, conf=0.86)
Experimental — accuracy not yet measured
- Premisecitation
Gut epithelial cells require physiologically relevant fluid shear stress (FSS) from the perfusion flow to express their organ cell functions.
“Practically gut epithelial cells require physiological relevant fluid shear stress (FSS) from the perfusion flow, to express their organ cell functions.14,15”
Quote in the paperSubstantial claim2 of 2 sources checked- cites [14] 2018, Cell. Mol. Gastroenterol. Hepatol source
The Microfluidic Intestine Chip Models section reports improved drug absorption and metabolic enzyme activity in response to apical fluid shear stress. The Mechanically Active Gut Chip Model section also describes intestinal functions under combined flow and peristalsis-like deformation. Neither establishes that fluid shear stress from perfusion is required for gut epithelial cells to express those functions. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [15] 2018, PLoS One source
In Results and discussion (page not provided), the paper reports that physiologically relevant perfusion shear appeared to induce Mucin-2 production in Caco-2 cells, unlike static Transwell cultures. That supports a role for flow in expressing one intestinal function, but not the broader claim that gut epithelial cells require it to express their organ functions generally; the Introduction also says Caco-2 cells differentiate and form tight monolayers in static Transwells. (LLM, conf=0.86)
Experimental — accuracy not yet measured
- Premisecitation
Current GLA-MPSs are based on two approaches: the cell-culture insert in microtiter plates and microfluidic devices.
“The current GLA-MPSs are based on two approaches: the cell-culture insert in the microtiter plates 7,11 and microfluidic devices.12,13”
Quote in the paperNot a substantial claim4 of 4 sources checked - Findingnone given
The circulation flow controlled by the micropump performed closed-loop circulation to interconnect the Caco-2 and HepG2 cell-culture chambers via a porous membrane.
“The circulation flow controlled by micropump performed closed-loop circulation to interconnect the Caco-2 and HepG2 cell-culture chambers via a porous membrane.”
Quote in the paperSubstantial claim - Findingown data
Caco-2 cells expressed ZO-1 tight junction protein to form the gut barrier.
“Caco-2 cells expressed ZO-1 tightjunction protein to form the gut barrier (Figure 6a);”
Quote in the paperSubstantial claim
- Findingown data
CFD simulations confirmed that physiologically relevant FSS (8 × 10-3 and 1.2 × 10-7 dyne cm-2) could be applied for gut (Caco-2) and liver (HepG2) cells, respectively.
“We analyzed the fluid shear stress (FSS) with computational fluid dynamics simulations and confirmed that the physiologically relevant FSS (i.e., 8 × 10 -3 and 1.2 × 10 -7 dyne cm -2 ) could be applied for the gut (Caco-2) and liver (HepG2) cells, respectively.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The cell-culture medium is an incompressible and homogeneous Newtonian fluid with conditions similar to water at 37 °C.
- The authors state this as an assumption: A 10-µm-thick layer covering the upper side of the porous membrane with no direct flow across via the interior wall setting models the cell layer.
- Rests on an assumption: The center cross-section along the gut chamber perfusion direction is representative for the CFD calculation.
- Findingnone given
The GLA-MPS integrates two cell culture chambers with individually applied perfusion flows and a circulation channel with an on-chip pneumatic micropump under cell culture chambers via a porous membrane for interconnecting them.
“Here, we introduce a GLA-MPS by integrating two cell culture chambers with individually applied perfusion flows and a circulation channel with an on-chip pneumatic micropump under cell culture chambers via a porous membrane for interconnecting them.”
Quote in the paperSubstantial claim - Findingown data
Circulation flow did not change ZO-1 expression in Caco-2 cells without perfusion flow.
“Further, the circulation flow did not change the ZO-1 expression in the Caco-2 cells without perfusion flow;”
Quote in the paperNot a substantial claim - Findingown data
The FSS was reduced dramatically with an increase in membrane thickness.
“The FSS was reduced dramatically with an increase in membrane thickness.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The cell-culture medium is an incompressible and homogeneous Newtonian fluid with conditions similar to water at 37 °C.
- The authors state this as an assumption: A 10-µm-thick layer covering the upper side of the porous membrane with no direct flow across via the interior wall setting models the cell layer.
- Rests on an assumption: The center cross-section along the gut chamber perfusion direction is representative for the CFD calculation.
- Findingown data
Under physiologically relevant flow, the Caco-2 and HepG2 cells enhanced the expression of functional proteins such as zonula occludens 1 (ZO-1) and albumin (ALB), respectively.
“further, they enhanced the expression of functional proteins such as zonula occludens 1 (ZO-1) and albumin (ALB), respectively.”
Quote in the paperSubstantial claim - Findingown data
When medium perfusion in the gut chamber was performed from 2 to 5 μL min-1, the surface FSS on the apical side of cells had a linear relationship with the external pumping flow rate.
“When the medium perfusion in the gut chamber was performed from 2 to 5 μL min -1 , the surface FSS on the apical side of cells had a linear relationship with the external pumping flow rate (Figure 3a and 3b).”
Quote in the paperSubstantial claim- The authors state this as an assumption: The cell-culture medium is an incompressible and homogeneous Newtonian fluid with conditions similar to water at 37 °C.
- The authors state this as an assumption: A 10-µm-thick layer covering the upper side of the porous membrane with no direct flow across via the interior wall setting models the cell layer.
- Rests on an assumption: The center cross-section along the gut chamber perfusion direction is representative for the CFD calculation.
- Findingown data
The FSS applied to cells from the basal side through the holes of the membrane was determined using the membrane thickness (h) and circulation flow rate.
“The FSS applied to cells from the basal side through the holes of the membrane was determined using the membrane thickness (h) and circulation flow rate (Figure 3c and d).”
Quote in the paperSubstantial claim- The authors state this as an assumption: The cell-culture medium is an incompressible and homogeneous Newtonian fluid with conditions similar to water at 37 °C.
- The authors state this as an assumption: A 10-µm-thick layer covering the upper side of the porous membrane with no direct flow across via the interior wall setting models the cell layer.
- Rests on an assumption: The center cross-section along the gut chamber perfusion direction is representative for the CFD calculation.
- Findingown data
The GLA-MPS disassembled when over 150 kPa was applied in the control layer for 14 days.
“the GLA-MPS had disassembled by applying over 150 kPa in the control layer for 14 days (data not shown).”
Quote in the paperSubstantial claim - Findingown data
Working frequencies over 1 Hz produced no significant differences in the generated flow rates.
“Working frequencies over 1 Hz exhibited no significant differences in the generated flow rates;”
Quote in the paperSubstantial claim - Findingown data
Under physiologically relevant flow, the Caco-2 and HepG2 cells in the GLA-MPS maintained a cell survival rate of 95% and 92%, respectively.
“Under physiologically relevant flow, the Caco-2 and HepG2 cells in the GLA-MPS maintained a cell survival rate of 95% and 92%, respectively;”
Quote in the paperSubstantial claim - Findingown data
Increasing perfusion flow rates in the gut cell culture chamber induced ZO-1 expression in Caco-2 cells at 5 μL min−1 (FSS = 2 × 10−2 dyne cm−2).
“the increase in flow rates of perfusion flows in the gut cell culture chamber induced the ZO-1 expression in the Caco-2 cells at 5 μL min -1 (FSS = 2 × 10 -2 dyne cm -2 ).”
Quote in the paperSubstantial claim - Findingown data
In the setup parameters (20-μm-thick membrane), the surface FSS (1 × 10-8 to 1.2 × 10-7 dyne cm-2) on the basal sides of cells by the circulation flow was considerably smaller than the FSS on the apical side of gut epithelial cells.
“In our setup parameters (20-µm-thick membrane), we found that the surface FSS (1 ×10 -8 to 1.2 × 10 -7 dyne cm -2 ) on the basal sides of cells by the circulation flow were considerably smaller than those of the FSS on the apical side of gut epithelial cells.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The cell-culture medium is an incompressible and homogeneous Newtonian fluid with conditions similar to water at 37 °C.
- The authors state this as an assumption: A 10-µm-thick layer covering the upper side of the porous membrane with no direct flow across via the interior wall setting models the cell layer.
- Rests on an assumption: The center cross-section along the gut chamber perfusion direction is representative for the CFD calculation.
- Findingnone given
The GLA-MPS device is fabricated with four-layered microfluidic structures: a cell-culture layer, porous membrane, circulation layer, and control layer with an on-chip micropump structure.
“The device is fabricated with four-layered microfluidic structures such as a cell-culture layer, porous membrane, circulation layer, and control layer with an on-chip micropump structure.”
Quote in the paperSubstantial claim - Findingown data
Caco-2 cells formed an intact cell barrier that protected against transportation of 4-kD FITC-dextran across the porous membrane.
“It indicated that Caco-2 cells formed an intact cell barrier to protect the transportation of 4-kD FITC-dextran across the porous membrane.”
Quote in the paperSubstantial claim - Findingown data
HepG2 cells did not change ALB expression by changing perfusion flow rates.
“HepG2 cells did not change the ALB expression by changing the perfusion flow rates (Figure 6b).”
Quote in the paperSubstantial claim - Findingown data
FSS by circulation flow was considerably smaller than FSS by perfusion flows.
“In light of the simulation results, FSS by circulation flow was considerably smaller than that by perfusion flows;”
Quote in the paperNot a substantial claim - Findingown data
Circulation flow induced ZO-1 expression in addition to perfusion flow.
“instead, it induced ZO-1 expression in addition to the perfusion flow.”
Quote in the paperSubstantial claim - Findingown data
Increasing circulation flow rates from 0 to 61 nL min−1 induced ALB expression in HepG2 cells.
“In contrast, the increase in circulation flow rates from 0 to 61 nL min-1 induced ALB expression in HepG2 cells.”
Quote in the paperSubstantial claim - Findingnone given
The on-chip micropump could realize a fine range of flow rate adjustment consistent with the FSS simulation circulation flow rate range.
“Besides, the on-chip micropump could realize a fine range of flow rate adjustment, which is consistent with the aforementioned FSS simulation circulation flow rate range.”
Quote in the paperSubstantial claim - Findingown data
The presented GLA-MPS device can form barrier tissue structure on a porous membrane.
“Here, we present a GLA-MPS device which can achieve individual physiological flow perfusion for each organ in the cell-culture chamber, form barrier tissue structure on a porous membrane, and connect two organs with circulation flow.”
Quote in the paperSubstantial claim - Findingown data
In this device, the exchange ratio of circulation flow rate to flow volume is 1.5% to 9% in 1 min.
“The exchange ratio is 1.5% to 9% in 1 min.”
Quote in the paperSubstantial claim - Findingnone given
The presented GLA-MPS device can achieve individual physiological flow perfusion for each organ in the cell-culture chamber.
“Here, we present a GLA-MPS device which can achieve individual physiological flow perfusion for each organ in the cell-culture chamber, form barrier tissue structure on a porous membrane, and connect two organs with circulation flow.”
Quote in the paperSubstantial claim - Findingown data
The presented GLA-MPS device can connect two organs with circulation flow.
“Here, we present a GLA-MPS device which can achieve individual physiological flow perfusion for each organ in the cell-culture chamber, form barrier tissue structure on a porous membrane, and connect two organs with circulation flow.”
Quote in the paperSubstantial claim - Findingown data
The mean FSS for the intestinal cells was in the range of 8 × 10-3 to 2 × 10-2 dyne cm-2.
“The mean FSS for the intestinal cells was in the range of 8 × 10 -3 to 2 × 10 -2 dyne cm -2 ,”
Quote in the paperSubstantial claim- The authors state this as an assumption: The cell-culture medium is an incompressible and homogeneous Newtonian fluid with conditions similar to water at 37 °C.
- The authors state this as an assumption: A 10-µm-thick layer covering the upper side of the porous membrane with no direct flow across via the interior wall setting models the cell layer.
- Rests on an assumption: The center cross-section along the gut chamber perfusion direction is representative for the CFD calculation.
- Findingown data
Caco-2 cells after 9-day culture under the optimal condition had cell barrier function.
“Using this optimal condition, we tested the permeability of Caco-2 cells after the 9-day culture, and we confirmed the cell barrier function (Figure 7).”
Quote in the paperSubstantial claim - Findingown data
The mean flow rate of the on-chip micropump increased with driving pressure from 0 to 150 kPa and pumping frequency from 0 to 1.5 Hz.
“The mean flow rate increased with driving pressure (0-150 kPa) and pumping frequency (0-1.5 Hz).”
Quote in the paperSubstantial claim - Findingown data
The selected flow rates (gut perfusion 2 μL min−1; circulation 61 nL min−1) provide the highest expression of functional proteins in both Caco-2 and HepG2 cells among the tested conditions.
“We select the flow rates (Gut perfusion flow: 2 µL min -1 ; circulation flow: 61 nL min -1 ) to establish in vitro GLA, which provides the highest expression of functional proteins in both Caco-2 and HepG2 cells among the tested conditions.”
Quote in the paperSubstantial claim - Interpretationreasoning
MPSs are suitable for recapitulating GLA in vitro.
“Therefore, MPSs are suitable for recapitulating GLA in vitro.”
Quote in the paperSubstantial claim - Premisecitation
MPSs provide physiologically relevant cellular microenvironments (soluble factors, perfusion, extracellular matrices, tissue-like structures, and physical stimuli) for cells and organs.
“The MPSs provide physiologically relevant cellular microenvironments (i.e., soluble factors, perfusion, extracellular matrices, tissue-like structures, and physical stimuli) for cells and organs, 5”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [5] 2018, Nat. Rev. Mater source
- Premisecitation
MPSs provide interconnecting organs via flow channels and controls.
“and interconnecting organs via flow channels and controls.6”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [6] 2015, Adv. Healthc. Mater source
- Interpretationreasoning
The GLA-MPS feature is advantageous for modelling multiple organ diseases such as inflammatory bowel disease (IBD) and non-alcoholic fatty liver disease (NAFLD).
“Further, this feature is advantageous for modelling multiple organ diseases such as inflammatory bowel disease (IBD) and non-alcoholic fatty liver disease (NAFLD).”
Quote in the paperSubstantial claim- Rests on an assumption: Effective drugs or treatments for IBD and NAFLD are not available because of the lack of mechanistic insights.
- Premisecitation
The microfluidic device cannot be applied to study organ molecular transport function across the gut barrier because it does not have an apical-to-basal side transport structure such as a porous membrane substrate on the bottom channel.
“Further, the device cannot be applied to study organ molecular transport function across the gut barrier because it does not have an apical to basal side transport structure such as a porous membrane substrate on the bottom channel.12”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [12] source
Checked before — its earlier verdict is held back until a new check runs.
- Interpretationreasoning
Cultured cells could receive FSS on their basal sides.
“however, the cultured cells could receive the FSS of basal sides.”
Quote in the paperSubstantial claim - Interpretationreasoning
In the GLA, a TEER sensor was beneficial for evaluating gut barrier formation and damage during disease progression.
“In the case of the GLA, the sensor for measuring trans-epithelial electrical resistance (TEER) was beneficial for evaluating gut barrier formation and causing damage during disease progression.”
Quote in the paperNot a substantial claim - Premisereasoning
In cell-culture insert systems, it is difficult to apply an appropriate uniform perfusion flow for the surface of each organ within the insert precisely because of its macroscopic millimeter scale and lack of perfusion controlling system.
“however, it is difficult to apply an appropriate uniform perfusion flow for surface of each organ within the insert precisely, because of its macroscopic scale in the millimeter range and lack of perfusion controlling system.”
Quote in the paperSubstantial claim - Interpretationnone given
The developed GLA-MPS platform can cultivate gut and liver cells separately with applied different perfusion flows/FSS to improve their cell viabilities and functionalities.
“We developed a GLA-MPS platform that can (i) cultivate gut and liver cells separately with applied different perfusion flows/FSS to improve their cell viabilities and functionalities, (ii) form barrier tissue, and (iii) interconnect GLA via circulation channels.”
Quote in the paperSubstantial claim - Interpretationreasoning
The induction of ZO-1 expression could be the outcome of combinations of FSS by perfusion/circulation flows and molecular transport.
“Thus, the induction of ZO-1 expression could be the outcome of the combinations of FSS by perfusion/circulation flows and molecular transport.”
Quote in the paperSubstantial claim - Premisecitation
PDMS meets the requirements as a structural material owing to its biocompatibility, gas permeability, and elasticity to realize micropumping.
“The PDMS meets the requirements as a structural material owing to its biocompatibility, gas permeability, and elasticity to realize micropumping.19”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [19] source
Checked before — its earlier verdict is held back until a new check runs.
- Interpretationreasoning
Therefore, precious patient samples such as biopsy specimens can be used efficiently.
“Therefore, we efficiently use precious patient samples, such as biopsy specimens.”
Quote in the paperSubstantial claim- Rests on an assumption: Patient-derived primary cells are limited in their ability to recapitulate patients' pathological conditions in vitro.
- Interpretationown data
The cells could be maintained with relatively high cell viability in this device.
“It demonstrated that the cells could be maintained relatively high cell viability in this device.”
Quote in the paperSubstantial claim - Interpretationown data
The developed GLA-MPS platform can interconnect GLA via circulation channels.
“We developed a GLA-MPS platform that can (i) cultivate gut and liver cells separately with applied different perfusion flows/FSS to improve their cell viabilities and functionalities, (ii) form barrier tissue, and (iii) interconnect GLA via circulation channels.”
Quote in the paperSubstantial claim - Premisecitation
In other GLA-MPSs, the exchange ratio is approximately 0.25% to 1% in 1 min.
“In other GLA-MPSs, 3,7 the exchange ratio is approximately 0.25% to 1% in 1 min.”
Quote in the paperSubstantial claim0 of 2 sources checked - Interpretationown data
Our device realized a more intensified circulation flow between the gut and liver than other GLA-MPSs.
“Thus, our device realized a more intensified circulation flow between the gut and liver.”
Quote in the paperSubstantial claim - Interpretationown data
The developed GLA-MPS platform can form barrier tissue.
“We developed a GLA-MPS platform that can (i) cultivate gut and liver cells separately with applied different perfusion flows/FSS to improve their cell viabilities and functionalities, (ii) form barrier tissue, and (iii) interconnect GLA via circulation channels.”
Quote in the paperSubstantial claim - Interpretationreasoning
For 9-day cell culture, the circulation flow is sufficient to induce interaction between the two organs in the GLA-MPS device.
“For 9-day cell culture, this flow is sufficient to induce the interaction between two organs in the GLA-MPS device.”
Quote in the paperSubstantial claim - Interpretationreasoning
This device allows modeling the GLA interaction as an in vitro model.
“This device allows modeling the GLA interaction as an in vitro model.”
Quote in the paperSubstantial claim - Interpretationown data
The GLA-MPS allows performing invasive cell-analytical methods such as immunocytochemistry and multi-omics analysis to obtain deeper insights into normal and diseased GLA.
“At the end of the experiments, GLA-MPS allows performing invasive cell-analytical methods such as immunocytochemistry, as shown in this paper, as well as multi-omics analysis (i.e., genomics, transcriptomics, proteomics, and metabolomics) to obtain deeper insights into normal and diseased GLA.”
Quote in the paperSubstantial claim - Interpretationown data
Both Caco-2 and HepG2 expressed better functions than in conventional cell culture settings when optimal flows and inter-tissue interactions were applied to establish in vitro GLA.
“Thus, both Caco-2 and HepG2 expressed better functions than those in the conventional cell culture settings by applying optimal flows and inter-tissue interactions to establish in vitro GLA.”
Quote in the paperSubstantial claim- Rests on an assumption: Conventional cell-culture methods have an unsolved challenge to activate in vitro cultured hepatocytes to express their in vivo physiological hepatic functions.
- Interpretationown data
Our approach using chemical and physical stimuli suggested a new way to obtain hepatic functions in vitro.
“Our approach using chemical and physical stimuli suggested a new way to obtain hepatic functions in vitro.”
Quote in the paperSubstantial claim- Rests on an assumption: Conventional cell-culture methods have an unsolved challenge to activate in vitro cultured hepatocytes to express their in vivo physiological hepatic functions.
- Interpretationnone given
The cell-culture medium in the circulation channel could accumulate molecules (growth factors, cytokines, metabolites, and lipids) and exosomes secreted from Caco-2 and HepG2 cells.
“The cell-culture medium in the circulation channel could accumulate molecules (i.e., growth factors, cytokines, metabolites, and lipids) and exosomes secreted from Caco-2 and HepG2 cells.”
Quote in the paperSubstantial claim - Interpretationnone given
The GLA-MPS allows collection of conditioned cell-culture media from two cell-culture chambers and circulation channels separately for investigating molecular mechanisms of GLA by biochemical assays such as ELISA and mass spectroscopy.
“Further, the presented GLA-MPS allows a collection of conditioned cell-culture media from two cell-culture chambers and circulation channels, separately, for investigating the underlying molecular mechanisms of the GLA by biochemical assays such as ELISA and mass spectroscopy.”
Quote in the paperSubstantial claim
- Classified as probably not a substantial claim. 21
- May combine two claims. 23
- The quote only partly states this claim. 1
Classified as probably not a substantial claim. May combine two claims.
PremisecitationGut microbiome plays critical roles in pathophysiological scenarios in the gut and can influence other organs such as the liver and the immune system.
“Gut microbiome 33 plays critical roles in the pathophysiological scenarios in the gut; they can influence other organs such as the liver 34,35 and the immune system 37 .”
Quote in the paperSubstantial claim1 of 4 sources checked- cites [33] 2020, Acta Pharm. Sin. B source
Checked before — its earlier verdict is held back until a new check runs.
- cites [34] 2019, Hepatol. Commun source
Checked before — its earlier verdict is held back until a new check runs.
- cites [35] source
- cites [37] source
Checked before — its earlier verdict is held back until a new check runs.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationIn cell-culture insert systems, cellular uptake and transport across the cell barrier can be studied with the porous membrane.
“For the cell-culture insert system, cellular uptake and transport across the cell barrier (e.g., endothelial cells and intestinal epithelial cells) can be studied with the porous membrane;”
Quote in the paperNot a substantial claim2 of 2 sources checked- cites [7] 2020, Cell Syst source
The STAR Methods describe intestinal epithelial monolayers grown on porous Transwell inserts, and the Results show that the system was used to study short-chain fatty acid passage across the gut barrier and its consumption by the gut model. The cited paper does not establish the sentence’s endothelial-cell example; its barrier experiments concern intestinal epithelium. (LLM, conf=0.84)
Experimental — accuracy not yet measured - cites [11] 2021, Micromachines source
Methods §2.6 describes using culture inserts to measure apical-to-basolateral transport in intestinal cells, and Results §3.2 calculates permeability using the membrane surface area. The paper does not show a cellular uptake assay or an endothelial-cell barrier experiment, so those examples extend beyond what it demonstrates. Page numbers are unavailable in our copy. (LLM, conf=0.84)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationThese microfluidic devices can apply only one flow rate for the introduced tissues although the gut and liver require different flow rates to realize their proper functions.
“for example, we can apply only one flow rate for the introduced tissues although the gut and liver require different flow rates to realize their proper functions.17,18”
Quote in the paperSubstantial claim1 of 2 sources checked- cites [17] 2019, IScience source
The Results section ('Computer Simulation Predicts Transepithelial Morphogen Gradient'; page unavailable) shows that intestinal epithelial morphogenesis varies with flow rate, supporting the point that flow conditions matter for gut tissue. The paper does not establish that gut and liver require different flow rates, or that a device containing both tissues can apply only one flow rate. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [18] 2017, Lab Chip source
May combine two claims.
FindingreasoningValve 2 is slower than valves 1 and 3, which leads to a peristaltic valve motion to generate output flow in one direction during actuation.
“Thus, valve 2 is slower than that of valves 1 and 3, which leads to a peristaltic valve motion to generate output flow in one-direction during actuation.”
Quote in the paperSubstantial claimMay combine two claims.
Findingnone givenThe presented MPS requires only 1.5 × 10^4 cells for each cell culture chamber, which is considerably smaller than 24-well cell culture inserts (3 × 10^5 cells).
“The presented MPS requires only 1.5 × 10 4 cells for each cell culture chamber, which is considerably smaller than those of the 24-well cell culture inserts (3 × 10 5 cells).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataAfter culture, Caco-2 and HepG2 cells showed 95% and 92% cell viability, respectively.
“After the culture, Caco-2 and HepG2 cells showed 95% and 92% cell viability, respectively (Figure 5b).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S4 (based).
Findingnone givenCaco-2 intestinal epithelial and HepG2 hepatocyte-like cells are applied to their own physiologically relevant FSSs for enhancing their functions, respectively.
“The Caco-2 intestinal epithelial and HepG2 hepatocyte-like cells are applied to their own physiologically relevant FSSs for enhancing their functions, respectively.”
Quote in the paperNot a substantial claimMay combine two claims.
FindingreasoningThe porous membrane separates the cell-culture chamber and circulation channel to perform two different flows; soluble factors are transported via holes.
“This membrane separates the cell-culture chamber and circulation channel to perform two different flows; soluble factors are transported via holes.”
Quote in the paperSubstantial claimThe quote only partly states this claim.
Findingown dataAt a 1-Hz working frequency and working pressure of 50 to 150 kPa, the circulation flow rates were 22 to 61 nL min−1.
“this gave flow rates from 22 to 61 nL min -1 for circulation at a 1-Hz working frequency.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.
Findingnone givenLow-temperature bonding causes less deformation on the PDMS block, which prevents shrinkage and bending, and leads to flat surfaces for multilayer bonding.
“Low-temperature bonding causes less deformations on the PDMS block, which prevents shrinkage and bending, and leads to flat surfaces for multilayer bonding.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationDisruption of GLA functions leads to liver disease progression and gastrointestinal disorders.
“The disruption of GLA functions leads to liver disease progression and gastrointestinal disorders.4”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [4] source
May combine two claims.
PremisecitationGLA regulates the absorption/prevention of exogenous agents at the gut barrier and metabolic processes in the liver.
“that regulates the absorption/prevention of exogenous agents at the gut barrier and metabolic processes in the liver.2,3”
Quote in the paperSubstantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationA number of MPSs as an in vitro GLA model (GLA-MPS) have been reported, such as GLA for metabolism and inflammation axes.
“Thus far, a number of MPSs as an in vitro GLA model (GLA-MPS) have been reported, such as GLA for metabolism and inflammation axess.3,7- 11”
Quote in the paperNot a substantial claim0 of 6 sources checked- cites [3] source
- cites [7] 2020, Cell Syst source
Checked before — its earlier verdict is held back until a new check runs.
- cites [8] source
Checked before — its earlier verdict is held back until a new check runs.
- cites [9] 2020, Lab Chip source
- cites [10] source
Checked before — its earlier verdict is held back until a new check runs.
- cites [11] 2021, Micromachines source
Checked before — its earlier verdict is held back until a new check runs.
Classified as probably not a substantial claim.
PremisecitationThe gut-liver-axis (GLA) is a bidirectional interaction between the gut and liver mediated by dietary, genetic, and environmental factors.
“The gut-liver-axis (GLA) is a bidirectional interaction between the gut and liver mediated by dietary, genetic, and environmental factors, 1”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [1] source
May combine two claims.
PremisecitationMPS features are critical to investigate the absorption, distribution, metabolism, excretion, and toxicity (ADME-T) of drug candidates and for disease modeling.
“These features are critical to investigate the absorption, distribution, metabolism, excretion, and toxicity (ADME-T) of the drug candidate and for disease modeling as well.6”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [6] 2015, Adv. Healthc. Mater source
May combine two claims.
InterpretationreasoningOur MPS is not limited to recapitulating only GLA but is also applicable to other organs and the microbiome.
“Thus, our MPS is not limited to recapitulate only GLA, but it is also applicable to other organs and the microbiome.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationGut-on-a-chips integrated with TEER measurements have been reported.
“Until now, gut-on-a-chips integrated with a TEER measurements have been reported.39,40”
Quote in the paperNot a substantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S2 (checkable).
Interpretationnone givenFlow perfusion conditions should be investigated for each organ's cells.
“The flow perfusion conditions should be investigated for each organ cells.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
PremisecitationFSS was one of the most important physical factors affecting cell function and morphology.
“The FSS was one of the most important physical factors affecting the cell function and morphology, 26,18”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
InterpretationreasoningThe GLA-MPS allows treating one tissue to induce disease phenotypes and investigating its effects on other tissues.
“We can treat one of the tissues to induce disease phenotypes and investigate its effects on other tissues.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim. May combine two claims.
InterpretationreasoningAn advanced in vitro GLA model requires (i) application of appropriate perfusion flow for the gut and liver, (ii) study of molecular transports across the gut barrier, and (iii) interconnection of the gut and liver to study their interactions within a single microfluidic device.
“Thus, there is an urgent need to fulfill these requirements for establishing an advanced in vitro GLA model that (i) enables the application of appropriate perfusion flow for the gut and liver, (ii) studies molecular transports across the gut barrier, and (iii) interconnects the gut and liver to study their interactions within a single microfluidic device.”
Quote in the paperSubstantial claim- Rests on an assumption: Gut and liver cells have cellular polarity, which should be functionalized in molecular transportation.
- Rests on an assumption: Circulation flow needs to connect two organs for inter-tissue interactions.
Probably not a substantial claim: may not pass S4 (based).
Study design and conductnone givenThe widely used cell lines Caco-2 and HepG2 can provide the standard performance of the presented GLA-MPS.
“In the present study, we used widely used cell lines (Caco-2 and HepG2) that can provide the standard performance of the presented GLA-MPS.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningThe circulation flow could be coupled with gut perfusion flow to improve cell function and induce organ-to-organ interaction for cell culture experiments.
“Therefore, we could couple the circulation flow with gut perfusion flow to improve the cell function and induce the organ to organ interaction for cell culture experiments.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationcitationThe GLA-MPS device's four-layered planar microfluidic structure allows integration of electrical read-out sensors in cell-culture chambers and circulation channel, enabling real-time and non-invasive monitoring of cell conditions and behaviors during culture and treatments.
“Owing to this feature, its another advantage is the capability to integrate electrical read-out sensors in cell-culture chambers and circulation channel, which allows monitoring cell conditions and behaviors during cell culture and treatments in a real-time and non-invasive fashion.38”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [38] 2019, iScience source
Checked before — its earlier verdict is held back until a new check runs.
May combine two claims.
Interpretationown dataHepG2 cells facilitated hepatic functions such as ALB production by FSS and molecular transport in the circulation channel.
“These results suggest that HepG2 cells facilitated hepatic functions such as ALB production by FSS, and as a molecular transport in the circulation channel.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Premisenone givenPrevious GLA-MPSs faced challenges in the control of FSS.
“but the previous GLA-MPSs faced challenges in the control.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S4 (based).
Interpretationnone givenThe device is suitable for demonstrating individual accessibility to investigate GLA interaction mediated by IBD and NAFLD.
“It is also suitable for demonstrating the individual accessibility to investigate the GLA interaction, mediated by IBD and NAFLD.”
Quote in the paperNot a substantial claim- Rests on an assumption: Effective drugs or treatments for IBD and NAFLD are not available because of the lack of mechanistic insights.
Probably not a substantial claim: may not pass S2 (checkable), S4 (based). May combine two claims.
Interpretationnone givenThe device is a more distinctive platform than the current GLA-MPS, resembling the physiological flow perfusion and circulation of in vivo GLA.
“The device is a more distinctive platform than the current GLA-MPS, resembling the physiological flow perfusion and circulation of in vivo GLA.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningThe medium contained both autocrine and paracrine factors and facilitated interactions of Caco-2 and HepG2 cells by the circulation flow.
“Thus, the medium contained both autocrine and paracrine factors and facilitated the interactions of Caco-2 and HepG2 cells by the circulation flow.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
InterpretationreasoningThe MPS device allows introduction of other tissue cells such as neurons and investigation of their interactions with the gut microbiome.
“Instead of liver cells; our MPS device allows the introduction of other tissue cells such as neurons, and we can investigate the interactions with the gut microbiome.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationUse of a microfluidic device allows control of perfusion flow in planar compartmentalized chambers and interconnection of two or more tissue cells via a microfluidic channel with an on-chip micropump.
“In contrast, the use of a microfluidic device allows the control of perfusion flow in the planar compartmentalized chambers and the interconnection of two or more tissue cells via a microfluidic channel with an on-chip micropump.12,13,16”
Quote in the paperSubstantial claim0 of 3 sources checkedProbably not a substantial claim: may not pass S4 (based). May combine two claims.
Premisenone givenIn cell-culture insert systems, under the porous membrane, a circulation channel could be used to connect two organs as well as apply flow perfusion.
“under porous membrane, a circulation channel could be used to connect two organs as well as apply flow perfusion;”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
PremisereasoningThere remain several concerns of flow perfusion control, organ functions, and inter-tissue interaction that need to be addressed for GLA-MPS.
“However, there remain several concerns of flow perfusion control, organ functions, and inter-tissue interaction that need to be addressed for GLA-MPS.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S2 (checkable).
InterpretationreasoningBecause patient-derived primary cells could have large patient-to-patient variations, it is beneficial to obtain standard datasets using commonly used cell lines.
“Since patient-derived primary cells could have large patient-to-patient variations, it would be beneficial to obtain such standard datasets with the use of commonly used cell lines.”
Quote in the paperNot a substantial claim- Rests on an assumption: Patient-derived primary cells could have large patient-to-patient variations.
May combine two claims.
Interpretationown dataConventional MPSs could not provide these results because of their drawbacks, whereas our MPS showed advantages over conventional MPSs.
“The conventional MPSs could not provide these results because of the aforementioned drawbacks of MPSs; our MPS showed advantages over the conventional MPSs.”
Quote in the paperNot a substantial claim- Rests on an assumption: Conventional cell-culture methods have an unsolved challenge to activate in vitro cultured hepatocytes to express their in vivo physiological hepatic functions.
Probably not a substantial claim: may not pass S4 (based).
Premisenone givenGut and liver cells have different physiologically relevant flow perfusion to be realized via precise flow control in the chip.
“First, gut and liver cells have different physiologically relevant flow perfusion to be realized via a precise flow control in the chip.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable).
InterpretationreasoningOur approach based on GLA-MPS has the potential for applications in understanding GLA mechanisms associated with individual physiological flow perfusion and multi-organ interactions for disease modeling.
“Finally, our approach based on GLA-MPS has the potential for applications in understanding the GLA mechanisms associated with individual physiological flow perfusion and multi-organ interactions for disease modeling.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Study design and conductnone givenIn this study, the fluorescent dye used to investigate gut barrier function might also influence cellular functions.
“In this study, we used a fluorescent dye to investigate gut barrier function; however, the dye might also influence cellular functions.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationcitationThe mean FSS range for intestinal cells was in the physiologically relevant range and could promote gut cell barrier formation and differentiation.
“which was in the physiologically relevant range 26,27 and could promote gut cell barrier formation and differentiation process.28,29”
Quote in the paperSubstantial claim0 of 4 sources checked
The paper relies on this without support.
Experimental animal models do not yield clear information about GLA because they have a whole set of organs that show complicated interactions in addition to GLA.
“However, using experimental animal models does not yield clear information about GLA because they have a whole set of organs that show complicated interactions in addition to GLA.”
The paper relies on this without support.
Gut and liver cells have cellular polarity, which should be functionalized in molecular transportation.
“Second, gut and liver cells have the cellular polarity, which should be functionalized in molecular transportation.”
The paper relies on this without support.
Circulation flow needs to connect two organs for inter-tissue interactions.
“Third, circulation flow needs to connect two organs for inter-tissue interactions.”
The paper relies on this without support.
MPSs recapitulate pathophysiological conditions in vitro by utilizing micro/nanotechnology approaches for applications in drug discovery.
“Microphysiological systems (MPSs) or organs-on-chips (OoCs) recapitulate pathophysiological conditions in vitro by utilizing micro/nanotechnology approaches for applications in drug discovery.”
The authors state this as an assumption.
The cell-culture medium is an incompressible and homogeneous Newtonian fluid with conditions similar to water at 37 °C.
“The cell-culture medium was considered an incompressible and homogeneous Newtonian fluid with conditions similar to water at 37 °C (density: 997 kg m -3 , viscosity: 6.9 × 10 -4 Pa s -1 ).”
The authors state this as an assumption.
A 10-µm-thick layer covering the upper side of the porous membrane with no direct flow across via the interior wall setting models the cell layer.
“A 10-µmthick layer covered the upper side of the porous membrane with no direct flow across via the interior wall setting to model the cell layer.”
The paper relies on this without support.
The center cross-section along the gut chamber perfusion direction is representative for the CFD calculation.
“The center cross-section along the gut chamber perfusion direction was used in the calculation;”
The paper relies on this without support.
There are seldom reports of GLA-MPSs used to investigate flow perfusion for cells on the apical side or flow on the basal side.
“However, so far, there are seldom reports of GLA-MPSs used to investigate the flow perfusion for cells on the apical side or flow on the basal side.”
The paper relies on this without support.
Conventional cell-culture methods have an unsolved challenge to activate in vitro cultured hepatocytes to express their in vivo physiological hepatic functions.
“The conventional cell-culture methods continue to have an important but unsolved challenge to activate in vitro cultured hepatocytes to express their in vivo physiological hepatic functions.”
The paper relies on this without support.
Effective drugs or treatments for IBD and NAFLD are not available because of the lack of mechanistic insights.
“Although it is well known that IBD 7 and NAFLD 35 are strongly associated with the gut microbiome, effective drugs or treatments are not available in the market because of the lack of mechanistic insights.”
The paper relies on this without support.
Patient-derived primary cells are limited in their ability to recapitulate patients' pathological conditions in vitro.
“These cells are limited in their ability to recapitulate the patients' pathological conditions in vitro.”
The paper relies on this without support.
Patient-derived primary cells could have large patient-to-patient variations.
“Since patient-derived primary cells could have large patient-to-patient variations, it would be beneficial to obtain such standard datasets with the use of commonly used cell lines.”
Cites
Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease
Cappello, V., Marchetti, L., Parlanti, P., Landi, S., Tonazzini, I., Cecchini, M., Piazza, V., & Gemmi, M. (2016) · Scientific Reports · doi:10.1038/s41598-016-0001-8 · Cited by 13,097 · see citing works
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · see citing works
Monolithic Microfabricated Valves and Pumps by Multilayer Soft Lithography
Unger, M., Chou, H.-P., Thorsen, T., Scherer, A., & Quake, S. R. (2000) · Science · doi:10.1126/science.288.5463.113 · Cited by 4,016 · see citing works
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166 · see citing works
Kim, H. J., Huh, D., Hamilton, G., & Ingber, D. E. (2012) · Lab on a Chip · doi:10.1039/c2lc40074j · Cited by 1,734 · see citing works
Sambuy, Y., Angelis, I. D., Ranaldi, G., Scarino, M. L., Stammati, A. P., & Zucco, F. (2005) · Cell Biology and Toxicology · doi:10.1007/s10565-005-0085-6 · Cited by 1,494 · see citing works
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480 · see citing works
Advantages and challenges of microfluidic cell culture in polydimethylsiloxane devices
Halldorsson, S., Lucumi, E., Gómez-Sjöberg, R., & Fleming, R. M. T. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.07.029 · Cited by 1,027 · see citing works
Advances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017 · see citing works
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777 · see citing works
Microfluidic Organ-on-a-Chip Models of Human Intestine
Bein, A., Shin, W., Jalili-Firoozinezhad, S., Park, M. H., Sontheimer-Phelps, A., Tovaglieri, A., Chalkiadaki, A., Kim, H. J., & Ingber, D. E. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.12.010 · Cited by 601 · see citing works
The gut microbiota is associated with immune cell dynamics in humans
Schluter, J., Peled, J. U., Taylor, B. P., Markey, K. A., Smith, M., Taur, Y., Niehus, R., Staffas, A., Dai, A., Fontana, E., et al. (2020) · Nature · doi:10.1038/s41586-020-2971-8 · Cited by 534 · see citing works
Henry, O. Y. F., Villenave, R., Cronce, M. J., Leineweber, W. D., Benz, M. A., & Ingber, D. E. (2017) · Lab on a Chip · doi:10.1039/c7lc00155j · Cited by 451 · see citing works
Microbiota modulate sympathetic neurons via a gut–brain circuit
Muller, P. A., Schneeberger, M., Matheis, F., Wang, P., Kerner, Z. J., Ilanges, A., Pellegrino, K., del Mármol, J. I., Castro, T. B. R., Furuichi, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2474-7 · Cited by 449 · see citing works
The gut microbiome: an orchestrator of xenobiotic metabolism
Collins, S. L., & Patterson, A. D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.001 · Cited by 341 · see citing works
Wu, X., Huang, X., Chen, R.-R., Tang, L., Ye, H., Xie, W., Huang, Z., & Cao, G. (2019) · Inflammation · doi:10.1007/s10753-019-01085-z · Cited by 276 · see citing works
Recent Advances in Body-on-a-Chip Systems
Sung, J. H., Wang, Y. I., Narasimhan Sriram, N., Jackson, M., Long, C., Hickman, J. J., & Shuler, M. L. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05293 · Cited by 258 · see citing works
Mimicking liver sinusoidal structures and functions using a 3D-configured microfluidic chip
Du, Y., Li, N., Yang, H., Luo, C., Gong, Y., Tong, C., Gao, Y., Lü, S., & Long, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01374k · Cited by 241 · see citing works
Fort, M. M., Mozaffarian, A., Stöver, A. G., Correia, J. D. S., Johnson, D. A., Crane, R. T., Ulevitch, R. J., Persing, D. H., Bielefeldt-Ohmann, H., Probst, P., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6416 · Cited by 216 · see citing works
Trapecar, M., Communal, C., Velazquez, J., Maass, C. A., Huang, Y.-J., Schneider, K., Wright, C. W., Butty, V., Eng, G., Yilmaz, O., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.02.008 · Cited by 204 · see citing works
Lentle, R. G., & Janssen, P. W. M. (2008) · Journal of Comparative Physiology B · doi:10.1007/s00360-008-0264-x · Cited by 200 · see citing works
Microfluidic Organ‐on‐a‐Chip Technology for Advancement of Drug Development and Toxicology
Caplin, J. D., Granados, N. G., James, M. R., Montazami, R., & Hashemi, N. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500040 · Cited by 195 · see citing works
Shin, W., Hinojosa, C. D., Ingber, D. E., & Kim, H. J. (2019) · iScience · doi:10.1016/j.isci.2019.04.037 · Cited by 190 · see citing works
Ohtani, N., & Kawada, N. (2019) · Hepatology Communications · doi:10.1002/hep4.1331 · Cited by 173 · see citing works
Integrated gut/liver microphysiological systems elucidates inflammatory inter‐tissue crosstalk
Chen, W. L. K., Edington, C., Suter, E., Yu, J., Velazquez, J. J., Velazquez, J. G., Shockley, M., Large, E. M., Venkataramanan, R., Hughes, D. J., et al. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26370 · Cited by 171 · see citing works
Delon, L. C., Guo, Z., Oszmiana, A., Chien, C.-C., Gibson, R., Prestidge, C., & Thierry, B. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119521 · Cited by 168 · see citing works
High-throughput compound evaluation on 3D networks of neurons and glia in a microfluidic platform
Wevers, N. R., van Vught, R., Wilschut, K. J., Nicolas, A., Chiang, C., Lanz, H. L., Trietsch, S. J., Joore, J., & Vulto, P. (2016) · Scientific Reports · doi:10.1038/srep38856 · Cited by 147 · see citing works
A multi-chamber microfluidic intestinal barrier model using Caco-2 cells for drug transport studies
Tan, H.-Y., Trier, S., Rahbek, U. L., Dufva, M., Kutter, J. P., & Andresen, T. L. (2018) · PLOS ONE · doi:10.1371/journal.pone.0197101 · Cited by 133 · see citing works
Integrated heart/cancer on a chip to reproduce the side effects of anti-cancer drugs in vitro
Kamei, K.-I., Kato, Y., Hirai, Y., Ito, S., Satoh, J., Oka, A., Tsuchiya, T., Chen, Y., & Tabata, O. (2017) · RSC Advances · doi:10.1039/c7ra07716e · Cited by 119 · see citing works
Self-citationFowler, S., Chen, W. L. K., Duignan, D. B., Gupta, A., Hariparsad, N., Kenny, J. R., Lai, W. G., Liras, J., Phillips, J. A., & Gan, J. (2020) · Lab on a Chip · doi:10.1039/c9lc00857h · Cited by 112 · see citing works
Permeability of Epithelial/Endothelial Barriers in Transwells and Microfluidic Bilayer Devices
Frost, T. S., Jiang, L., Lynch, R. M., & Zohar, Y. (2019) · Micromachines · doi:10.3390/mi10080533 · Cited by 105 · see citing works
Yang, J., Hirai, Y., Iida, K., Ito, S., Trumm, M., Terada, S., Sakai, R., Tsuchiya, T., Tabata, O., & Kamei, K.-I. (2023) · Communications Biology · doi:10.1038/s42003-023-04710-8 · Cited by 98 · see citing works
Self-citationProt, J. M., Maciel, L., Bricks, T., Merlier, F., Cotton, J., Paullier, P., Bois, F. Y., & Leclerc, E. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25232 · Cited by 89 · see citing works
Moving mask UV lithography for three-dimensional structuring
Hirai, Y., Inamoto, Y., Sugano, K., Tsuchiya, T., & Tabata, O. (2006) · Journal of Micromechanics and Microengineering · doi:10.1088/0960-1317/17/2/003 · Cited by 85 · see citing works
Self-citationA Human Liver‐on‐a‐Chip Platform for Modeling Nonalcoholic Fatty Liver Disease
Lasli, S., Kim, H., Lee, K., Suurmond, C. E., Goudie, M. J., Bandaru, P., Sun, W., Zhang, S., Zhang, N., Ahadian, S., et al. (2019) · Advanced Biosystems · doi:10.1002/adbi.201900104 · Cited by 85 · see citing works
Publisher Correction: The gut–liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0031-8 · Cited by 68 · see citing works
Soucy, J. R., Bindas, A. J., Koppes, A. N., & Koppes, R. A. (2019) · iScience · doi:10.1016/j.isci.2019.10.052 · Cited by 61 · see citing works
A Minimized Valveless Electromagnetic Micropump for Microfluidic Actuation on Organ Chips
Mi, S., Pu, H., Xia, S., & Sun, W. (2020) · Sensors and Actuators A: Physical · doi:10.1016/j.sna.2019.111704 · Cited by 60 · see citing works
Transport phenomena of microbial flora in the small intestine with peristalsis
Ishikawa, T., Sato, T., Mohit, G., Imai, Y., & Yamaguchi, T. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.03.026 · Cited by 59 · see citing works
Design and dynamic characterization of “single-stroke” peristaltic PDMS micropumps
Lai, H., & Folch, A. (2010) · Lab on a Chip · doi:10.1039/c0lc00023j · Cited by 57 · see citing works
Arakawa, H., Sugiura, S., Kawanishi, T., Shin, K., Toyoda, H., Satoh, T., Sakai, Y., Kanamori, T., & Kato, Y. (2020) · Lab on a Chip · doi:10.1039/c9lc00884e · Cited by 49 · see citing works
Shinha, K., Nihei, W., Nakamura, H., Goto, T., Kawanishi, T., Ishida, N., Yamazaki, N., Imakura, Y., Mima, S., Inamura, K., et al. (2021) · Micromachines · doi:10.3390/mi12091007 · Cited by 35 · see citing works
On-ratio PDMS bonding for multilayer microfluidic device fabrication
Lai, A., Altemose, N., White, J. A., & Streets, A. (2019) · Journal of Micromechanics and Microengineering · doi:10.1088/1361-6439/ab341e · Cited by 34 · see citing works
Microtechnology-based in vitro models: Mimicking liver function and pathophysiology
Lee, S. Y., Kim, D., Sung, J. H., & Sung, J. H. (2021) · APL Bioengineering · doi:10.1063/5.0061896 · Cited by 21 · see citing works
Hirai, Y., Takagi, D., Anai, S., Chihara, Y., Tsuchiya, T., Fujimoto, K., Hirao, Y., & Tabata, O. (2015) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2015.01.118 · Cited by 13 · see citing works
Self-citationMiyazaki, T., Hirai, Y., Kamei, K., Tsuchiya, T., & Tabata, O. (2020) · Electronics and Communications in Japan · doi:10.1002/ecj.12296 · Cited by 11 · see citing works
Self-citationYang, J., Hirai, Y., Iida, K., Ito, S., Trumm, M., Terada, S., Sakai, R., Tsuchiya, T., Tabata, O., & Kamei, K.-I. (2020) · doi:10.1101/2020.06.10.141606 · Cited by 4 · see citing works
Self-citation(2021) · Electronics and Communications in Japan · doi:10.1002/ecj.12251 · Cited by 2 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- 2006, J. Micromechanics Microengineering, 17, 199
- 2019, Adv. Biosyst, 3, 1
Cited by
Sorted by citations
Yang, J., Hirai, Y., Iida, K., Ito, S., Trumm, M., Terada, S., Sakai, R., Tsuchiya, T., Tabata, O., & Kamei, K.-I. (2023) · Communications Biology · doi:10.1038/s42003-023-04710-8 · Cited by 98 · see citing works
Self-citationRecent Advances in Gut‐ and Gut–Organ‐Axis‐on‐a‐Chip Models
Kim, R., & Sung, J. H. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302777 · Cited by 42 · see citing works
Liver-on-chips for drug discovery and development
Mehta, V., Karnam, G., & Madgula, V. L. M. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101143 · Cited by 40 · see citing works
Advances in 3D Bioprinting and Microfluidics for Organ-on-a-Chip Platforms
de Barros, N. R., Harb, S. V., Horinouchi, C. D. D. S., Tofani, L. B., Santos, D., Elias, G. B., Velho, J. C. M., de Aguiar, A. C., Sant’Ana, M., & Figueira, A. C. M. (2025) · Polymers · doi:10.3390/polym17223078 · Cited by 32 · see citing works
Microfluidic gut-axis-on-a-chip models for pharmacokinetic-based disease models
Kim, R., & Sung, J. H. (2024) · Biomicrofluidics · doi:10.1063/5.0206271 · Cited by 12 · see citing works
Negoro, R., Deguchi, S., Yamazaki, D., Takayama, K., & Fujita, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-22425-0 · Cited by 10 · see citing works
Gut-on-chip and liver-on-chip platforms for pathophysiological modeling
Coricciati, C., Mello, E., Luca, E. D., Gigli, G., Rainer, A., & Mozetic, P. (2025) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2025.100601 · Cited by 9 · see citing works
Multi-organ-on-a-chip: Modeling strategy, method, and biomedical applications
Gao, X., Wang, T., Huang, W., Liu, C., Zhang, Z., Deng, Y., & Huang, J. (2025) · Biomicrofluidics · doi:10.1063/5.0282055 · Cited by 9 · see citing works
He, H., Hong, M., Yang, F., Wang, G., Wang, Y., Yang, M., Huang, D., Hong, L., & Wang, Y. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00516 · Cited by 6 · see citing works
In vitro models of the gut-liver axis: what we’ve learned and what remains to be built
Sung, J. H., & Kim, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1858289 · Cited by 2 · see citing works
Yu, Y., Lin, T., Ye, X., Wang, Y., Xiao, R., Sun, B., Zhao, M., Song, J., Bo, L., & Zhou, X. (2026) · Lab on a Chip · doi:10.1039/d5lc01094b · Cited by 1 · see citing works
Yan, R., Gao, G., Deng, Y., Li, J., & Li, Y. (2025) · Biosensors · doi:10.3390/bios16010023 · Cited by 1 · see citing works
Body on a Chip Development Based on Nano/Microfabrication
Hirai, Y. (2023) · Journal of the Japan Society for Precision Engineering · doi:10.2493/jjspe.89.690
Self-citationSchüler, J. B., Sjöman, H., & Kriesi, C. (2024) · Communications Biology · doi:10.1038/s42003-024-05843-0
Body on a Chip to Elucidate the Disease Mechanisms via Inter-tissue Communications
Kamei, K. (2024) · The Journal of the Institute of Electrical Engineers of Japan · doi:10.1541/ieejjournal.144.199
Self-citationBao, C., Ren, Y., Zhao, W., Duan, J., & Han, X. (2026) · Science of Traditional Chinese Medicine · doi:10.1097/st9.0000000000000131
Liver-on-Chip: An Analysis of Liver Cell Types, Seeding Parameters, and Liver Function Assays
Gyeltshen, T. C., Sajin, D., & Ta, H. T. (2026) · Micromachines · doi:10.3390/mi17070769
Tan, H. Y., Hwang, I. Y., Jayabalan, N., Lee, H. L., Ong, L. J. Y., Lim, C. T., Chang, M. W., & Toh, Y. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71442
Lee, C.-J., Kim, Y., Kim, M., Rim, Y. A., & Ju, J. H. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70162
Network Biology: Current Status, Applications, Challenges, and Future Prospects
Li, X., Zhang, L., Ding, Y., Li, K., Chang, S., Pei, L., Li, Z., & Chen, Z. (2026) · MedComm · doi:10.1002/mco2.71065
Shrestha, A. P., Mathur, S., Duarte, S. M., & Zarrinpar, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-16110-0.00020-0
- Authors
- Yang, J., Hirai, Y., Imamura, S., Tsuchiya, T., Tabata, O., & Kamei, K.-I.
- Affiliations
- Kyoto University (JP)
- Institute for Integrated Cell-Material Sciences, Kyoto University (JP)
- Shenyang Pharmaceutical University (CN)
- ORCID
- Venue
- Biomicrofluidics
- Publisher
- openRxiv
- Published
- 2022-02-02
- Volume
- 16
- Issue
- 4
- Pages
- 044113-044113
- ISSN
- 1932-1058 (ISSN-L)
- PMC
- PMC9420048
- OpenAlex
- W4293124489
- Semantic Scholar
- 6fc5556f02f328927dff7663c25580985a77e95b
- Cited by
- 21
- References
- 47
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 6 · 2023: 2
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Biomicrofluidics (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (17937667)
- Ebara Hatakeyama Memorial Foundation
- Ministry of Education, Culture, Sports, Science and Technology
- Liaoning Revitalization Talents Program (XLYC1902061)
- Japan Society for the Promotion of Science (18KK0306, 17H02083, and 21H01728, 19H02572, 21H01728)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- gut-liver axis, microphysiological systems, fluid shear stress, Caco-2 cells, HepG2 cells, perfusion flow, zonula occludens-1, albumin expression, inflammatory bowel disease, lipopolysaccharide, inducible nitric oxide synthase, in vitro disease model, organ-on-a-chip
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-11-06.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-11-06.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review